At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET
Xenon Pharmaceuticals announced its participation in four upcoming investor conferences in Q4 2026, with no financial results or material business updates disclosed. The press release is a routine corporate communication with no impact on the company's fundamentals.
- Xenon will present at four investor conferences in Q4 2026: Guggenheim, Stifel, Jefferies, and Evercore.
- No financial results, guidance, or material business developments were disclosed.
- The company's lead molecule is azetukalner, a KV7 potassium channel opener in late-stage development for epilepsy and depression.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access